Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Barriers to Care: New Medications and CKD.
Kim D, Perkovic V, Kotwal S. Kim D, et al. Among authors: kotwal s. Kidney Int Rep. 2023 Dec 16;9(3):504-507. doi: 10.1016/j.ekir.2023.12.012. eCollection 2024 Mar. Kidney Int Rep. 2023. PMID: 38481511 Free PMC article. No abstract available.
Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data.
Neuen BL, Jun M, Wick J, Kotwal S, Badve SV, Jardine MJ, Gallagher M, Chalmers J, Nallaiah K, Perkovic V, Peiris D, Rodgers A, Woodward M, Ronksley PE. Neuen BL, et al. Among authors: kotwal s. Lancet Reg Health West Pac. 2023 Dec 18;43:100988. doi: 10.1016/j.lanwpc.2023.100988. eCollection 2024 Feb. Lancet Reg Health West Pac. 2023. PMID: 38192747 Free PMC article.
Health-related quality of life after a diagnosis of bladder cancer: a longitudinal survey over the first year.
Rogers Z, Glaser A, Catto JWF, Bottomley S, Jubber I, Kotwal S, Brittain P, Gill J, Rogers MA, Dooldeniya MD, Koenig P, Cresswell J, Chahal R, Bryan N, Smith NJ, Pritchard K, Abbasi Z, Mason SJ, Absolom K, Downing A. Rogers Z, et al. Among authors: kotwal s. BJU Int. 2024 Apr;133(4):460-473. doi: 10.1111/bju.16242. Epub 2023 Dec 13. BJU Int. 2024. PMID: 38031657 Free article.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
172 results